Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Asset Writedowns and Impairment (2018 - 2022)

Historic Asset Writedowns and Impairment for Organogenesis Holdings (ORGO) over the last 6 years, with Q2 2024 value amounting to $18.8 million.

  • Organogenesis Holdings' Asset Writedowns and Impairment changed N/A to $18.8 million in Q2 2024 from the same period last year, while for Dec 2024 it was $18.8 million, marking a year-over-year increase of 1554426.23%. This contributed to the annual value of $18.8 million for FY2024, which is N/A changed from last year.
  • Per Organogenesis Holdings' latest filing, its Asset Writedowns and Impairment stood at $18.8 million for Q2 2024.
  • In the past 5 years, Organogenesis Holdings' Asset Writedowns and Impairment registered a high of $18.8 million during Q2 2024, and its lowest value of -$1.4 million during Q4 2020.
  • Over the past 4 years, Organogenesis Holdings' median Asset Writedowns and Impairment value was $632000.0 (recorded in 2021), while the average stood at $1.8 million.
  • Per our database at Business Quant, Organogenesis Holdings' Asset Writedowns and Impairment skyrocketed by 293750.0% in 2020 and then crashed by 23528.48% in 2022.
  • Organogenesis Holdings' Asset Writedowns and Impairment (Quarter) stood at -$1.4 million in 2020, then skyrocketed by 145.93% to $632000.0 in 2021, then tumbled by 235.28% to -$855000.0 in 2022, then skyrocketed by 2303.74% to $18.8 million in 2024.
  • Its Asset Writedowns and Impairment stands at $18.8 million for Q2 2024, versus -$855000.0 for Q4 2022 and $733000.0 for Q3 2022.